Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Novartis’ Cosentyx gets approval in Japan
Cosentyx approval is based on phase III programme demonstrating high, sustained efficacy in the skin clearance of…
20 Years
In Express Pharma’s 20th year, we present the second installment of thought leaders predicting changes to watch out for in the…
‘The health industry as a whole has a positive future’
In a free-wheeling conversation with Viveka Roychowdhury, Patrick Figgis, Global Health Leader, PwC and Sujay Shetty,…
Issues and trends in the Indian pharma industry
There is a dire need for carefully balancing the requirements of the public and the industry, opine Bhavik Narsana, Partner,…
Recent surge in pharma patent litigation
The next decade or so in the pharmaceutical patent space in India will be interesting to watch out for. As more product patents…
Novartis India reports loss for the quarter ended 31 December 2014
During the quarter under review, profit before tax was Rs 4.4 crore as against Rs 21.6 crore in the previous corresponding period…
Biotech Special
The last few years have been painful for India’s biotech sector but many companies have turned adversity into opportunity. Express…
Panacea Biotec: A Turnaround Story
After three consecutive years of negative EBITDA, Panacea Biotec looks set to script a successful revival. Dr Rajesh Jain, Joint…
Fermenta Biotech Limited: Tough gets going
Since the past few years, lack of funding, distrustful investors, and weak global economic conditions have made survival a tall…
Evolva Biotech: Evolving Spirit
Providing innovative, high value, sustainable ingredients, in particular for the health, wellness and nutrition segment, Evolva…